Clinical

  1. Clinical

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer’s Association International Conference® 2024 (AAIC®)

SOUTH SAN FRANCISCO, Calif., July 28, 2024 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the presentation of a poster on baseline characteristics for the global INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease […]
Written by
  1. Clinical

Presage Biosciences Announces First Patient Dosing of Pure Biologics’ ROR1 Targeting Antibody For Treatment of Cancer

SEATTLE, July 25, 2024. Presage Biosciences, a biotechnology company that directly measures activity of oncology drugs within human tumors, announced the Phase 0 dosing of the first cancer patient with Pure Biologics’ PBA-0405, an antibody that targets ROR1. PBA-0405 has been engineered to induce tumor cell killing by cytotoxic immune cells. This exploratory study is […]
Written by
  1. Clinical

Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia

SAN DIEGO, July 24, 2024. Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer’s disease, today announced final results from its Phase 2 study of TPN-101 in patients with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) related to hexanucleotide repeat […]
Written by
  1. Clinical

TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia

EDINBURGH, Scotland, July 22, 2024. TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on July 16, the sixth patient in ACHIEVE (UK) was treated. This is the first patient treated with a higher dose […]
Written by
  1. Clinical

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

CARLSBAD, Calif., July 18, 2024. Ionis Pharmaceuticals, Inc. announced today that it has completed enrollment in the pivotal trial of zilganersen (ION373), an investigational RNA-targeted medicine in development for the treatment of children and adults with a rare, progressive and ultimately fatal neurological disorder known as Alexander disease (AxD). The primary endpoint is percent change […]
Written by
  1. Clinical

FDA Clears Investigational New Drug application for muscular dystrophy treatment

MINNEAPOLIS and ST. PAUL, Minn., July 17, 2024. Today, Myogenica, a University of Minnesota startup company, announced U.S. Food and Drug Administration approval for an Investigational New Drug (IND) application for MyoPAXon — an induced pluripotent stem cell-derived muscle stem cell product to regenerate skeletal muscle. A pending clinical trial would evaluate the safety, tolerability […]
Written by
  1. Clinical

Immunotherapy Approach Shows Potential in Some People with Metastatic Solid Tumors

July 11, 2024 — Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may be effective in treating metastatic solid tumors. In the trial, researchers from the National Institutes of Health (NIH) genetically engineered normal white blood cells, known as lymphocytes, from each patient to produce receptors that recognize […]
Written by
  1. Clinical

Niclosamide-based Metabolic Anticancer Drug’s First Clinical Trial Target are Prostate Cancer Patients Resistant to Hormone Therapy

SEOUL, South Korea, July 11, 2024. ADM Korea, a subsidiary of Hyundai Bioscience, announced on the 8th that the first clinical trial target population for its niclosamide-based oral metabolic anticancer drug will be ‘prostate cancer patients resistant to hormone therapy.’ Metabolic anticancer drugs regulate the metabolic pathways of cancer cells to induce their death. The […]
Written by
  1. Clinical

AskBio receives FDA Fast Track and MHRA Innovation Passport Designations for AB-1005 Investigational GDNF Gene Therapy for Parkinson’s Disease

Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 – Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track Designation for AB-1005, which is […]
Written by
  1. Clinical

Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors

DAEJEON, South Korea, July 8, 2024. PharmAbcine Inc., a clinical-stage biotech company focusing on next-generation antibody therapeutics, announced that PMC-309, VISTA-targeting immuno-oncology program, received safety approval for the first dose cohort (0.2mg/kg) in Phase 1a/b clinical trial for patients with advanced or metastatic solid tumors in Australia. The second dose cohort (0.5mg/kg) is currently ongoing. […]
Written by

Good Reads

Curevac_2ndgen.jpg

From Brisbane to London to Paris: Vicebio´s Sanofi deal

What began in the labs of the University of Queensland has now set the stage for one of Europe’s largest biotech acquisitions of the year. Sanofi has announced it will acquire UK-based vaccine developer Vicebio for $1.15 billion upfront, with an additional $450 million tied to clinical milestones—underscoring a major commitment to next-generation respiratory vaccines. […]
Written by

The Unkempt RNA-binding protein reveals a local translation program in centriole overduplication

Excess centrosomes cause defects in mitosis, cell-signaling, and cell migration, and therefore their assembly is tightly regulated. The divergent Polo kinase, PLK4, controls centriole duplication at the heart of centrosome assembly, and elevated PLK4 levels promote centrosome amplification (CA), a founding event of tumorigenesis. Here, we investigate the transcriptional consequences of elevated PLK4 and find […]
Written by

Worlwide

Curevac_2ndgen.jpg

From Brisbane to London to Paris: Vicebio´s Sanofi deal

What began in the labs of the University of Queensland has now set the stage for one of Europe’s largest biotech acquisitions of the year. Sanofi has announced it will acquire UK-based vaccine developer Vicebio for $1.15 billion upfront, with an additional $450 million tied to clinical milestones—underscoring a major commitment to next-generation respiratory vaccines. […]
Written by

The Unkempt RNA-binding protein reveals a local translation program in centriole overduplication

Excess centrosomes cause defects in mitosis, cell-signaling, and cell migration, and therefore their assembly is tightly regulated. The divergent Polo kinase, PLK4, controls centriole duplication at the heart of centrosome assembly, and elevated PLK4 levels promote centrosome amplification (CA), a founding event of tumorigenesis. Here, we investigate the transcriptional consequences of elevated PLK4 and find […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.